Nuvalent, Inc. (NUVL) Stock Score, Valuation & Financial Research

Nuvalent, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NUVL

Nuvalent, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 123.96. These figures are a research snapshot, not a buy or sell recommendation.

What Nuvalent, Inc. does

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Nuvalent is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future milestone payments or royalties from collaborative agreements to fund the research and development of its pipeline of targeted kinase inhibitors for cancer treatment.

Products and services

  • The company is developing a pipeline of small-molecule kinase inhibitors, including zidesamtinib (NVL-520) for ROS1-positive NSCLC, neladalkib (NVL-655) for ALK-positive NSCLC, and NVL-330 for HER2-mutant NSCLC.

Brands and product families

  • Zidesamtinib — Lead clinical-stage candidate for ROS1-positive NSCLC. Source
  • Neladalkib — Clinical-stage candidate for ALK-positive NSCLC. Source
  • NVL-330 — Clinical-stage candidate for HER2-mutant NSCLC. Source

Customer types

Clinical trial patients; Healthcare providers and oncology centers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of drug substances and drug products for clinical trials. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — Companies developing targeted therapies for oncology, specifically those targeting ROS1, ALK, and HER2 mutations in non-small cell lung cancer. Source

Business strengths to evaluate

  • Proprietary kinase-focused drug design platform Source
  • Experienced management team in oncology drug development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NUVL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 123.96
Market capitalization:
9.13B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -450.07M
Free cash flow:
USD -275.21M
Cash:
USD 159.73M
Total debt:
USD 0.00
EPS:
USD -6.06

What stands out

  • Free cash flow is USD -275.21M, negative for the stored period.
  • The balance sheet shows USD 159.73M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 159.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NUVL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NUVL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NUVL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NUVL to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of NUVL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research NUVL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.